» Articles » PMID: 27935872

Feasibility of a Novel One-stop ISET Device to Capture CTCs and Its Clinical Application

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 Dec 10
PMID 27935872
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Circulating tumor cells (CTCs) play a crucial role in cancer metastasis. In this study, we introduced a novel isolation method by size of epithelial tumor cells (ISET) device with automatic isolation and staining procedure, named one-stop ISET (osISET) and validated its feasibility to capture CTCs from cancer patients. Moreover, we aim to investigate the correlation between clinicopathologic features and CTCs in colorectal cancer (CRC) in order to explore its clinical application.

Results: The capture efficiency ranged from 80.3% to 88% with tumor cells spiked into medium while 67% to 78.3% with tumor cells spiked into healthy donors' blood. In detection blood samples of 72 CRC patients, CTCs and clusters of circulating tumor cells (CTC-clusters) were detected with a positive rate of 52.8% (38/72) and 18.1% (13/72) respectively. Moreover, CTC positive rate was associated with factors of lymphatic or venous invasion, tumor depth, lymph node metastasis and TNM stage in CRC patients (p < 0.01). Lymphocyte count and neutrophil to lymphocyte ratio (NLR) were significantly different between CTC positive and negative groups (p < 0.01).

Materials And Methods: The capture efficiency of the device was tested by spiking cancer cells (MCF-7, A549, SW480, Hela) into medium or blood samples of healthy donors. Blood samples of 72 CRC patients were detected by osISET device. The clinicopathologic characteristics of 72 CRC patients were collected and the association with CTC positive rate or CTC count were analyzed.

Conclusions: Our osISET device was feasible to capture and identify CTCs and CTC-clusters from cancer patients. In addition, our device holds a potential for application in cancer management.

Citing Articles

Microfluidics engineering towards personalized oncology-a review.

Mishra S, Kumarasamy M In Vitro Model. 2025; 2(3-4):69-81.

PMID: 39871996 PMC: 11756504. DOI: 10.1007/s44164-023-00054-z.


Combined microfluidic enrichment and staining workflow for single-cell analysis of circulating tumor cells in metastatic prostate cancer patients.

Loppke C, Jorgensen A, Sand N, Klitgaard R, Daugaard G, Agerbaek M Sci Rep. 2024; 14(1):17501.

PMID: 39080445 PMC: 11289449. DOI: 10.1038/s41598-024-68336-4.


Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence.

Tsai K, Huang P, Chu P, Nguyen T, Hung H, Hsieh C Cancers (Basel). 2024; 16(13).

PMID: 39001379 PMC: 11240518. DOI: 10.3390/cancers16132316.


The integrated on-chip isolation and detection of circulating tumour cells.

Abusamra S, Barber R, Sharafeldin M, Edwards C, Davis J Sens Diagn. 2024; 3(4):562-584.

PMID: 38646187 PMC: 11025039. DOI: 10.1039/d3sd00302g.


Expression of PTP4A1 in circulating tumor cells and its efficacy evaluation in patients with early- and intermediate-stage esophageal cancer.

Wu J, Wang W, Zhou Y, Yang D, Wu Z, Li X Medicine (Baltimore). 2023; 102(51):e36603.

PMID: 38134119 PMC: 10735090. DOI: 10.1097/MD.0000000000036603.


References
1.
Stott S, Lee R, Nagrath S, Yu M, Miyamoto D, Ulkus L . Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010; 2(25):25ra23. PMC: 3141292. DOI: 10.1126/scitranslmed.3000403. View

2.
Krebs M, Hou J, Sloane R, Lancashire L, Priest L, Nonaka D . Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2011; 7(2):306-15. DOI: 10.1097/JTO.0b013e31823c5c16. View

3.
Scher H, Jia X, de Bono J, Fleisher M, Pienta K, Raghavan D . Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10(3):233-9. PMC: 2774131. DOI: 10.1016/S1470-2045(08)70340-1. View

4.
de Albuquerque A, Kubisch I, Stolzel U, Ernst D, Boese-Landgraf J, Breier G . Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med. 2012; 10:222. PMC: 3508882. DOI: 10.1186/1479-5876-10-222. View

5.
Gorges T, Tinhofer I, Drosch M, Rose L, Zollner T, Krahn T . Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 2012; 12:178. PMC: 3502112. DOI: 10.1186/1471-2407-12-178. View